Global Allergic Conjunctivitis Report 2019 - API Manufacturers, Marketed and Phase III Drugs Landscape - ResearchAndMarkets.com

January 24, 2019

DUBLIN--(BUSINESS WIRE)--Jan 24, 2019--The “Allergic Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about marketed and Phase III products for Allergic Conjunctivitis . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Allergic Conjunctivitis

Coverage of API manufacturers for Allergic Conjunctivitis marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Allergic Conjunctivitis

This report provides a comprehensive understanding of the emerging Phase III therapies for Allergic Conjunctivitis which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2021.


A review of the marketed products for Allergic Conjunctivitis including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2021 and API manufacturer details. Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details API manufacturers for the marketed products with location details Emerging Phase III product profiles for Allergic Conjunctivitis including product description, developmental activities, licensors & collaborators and chemical information

Key Topics Covered:

1. Report Introduction

2. Allergic Conjunctivitis: Overview

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

5. Emerging Therapies (Phase III)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wcb57v/global_allergic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190124005348/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs ,Optical Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/24/2019 06:29 AM/DISC: 01/24/2019 06:29 AM


Update hourly